FindTrial
Sign In

To evaluate the Effects of Two Unani Medicines, tablet Banadiq al buzoor ,Sharbat Aalu Balu with Allopathic Medicine Cap. Nitrofurantoin for Treating Simple Urinary Tract Infections (UTIs)

An Open Label Randomized Standard Controlled Clinical Study to Assess the Synergistic Efficacy of Two Unani Formulations in the Management of Uncomplicated Urinary Tract Infection (Tadiya-e-Aalat-e-Baul) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075079
Enrollment
60
Registered
2024-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified Health Condition 2: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Tab. Banadiq al buzoor along with Sharbat Aalu Balu: tablet Banadiq al buzoor 2 tab. twice a day along with Sharbat Aalu Balu 20 ml for 21 days. Control Intervention1: Cap. Nitrofurant

Sponsors

Govt Tibbi College and Hospital Kadamkuan Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed patient of Uncomplicated UTIs by urine culture and sensitivity . 2. Patients of either gender between the age group of 18 to 65 years. 3. Patient willing to sign the written informed consent to participate in trial. 4. Patient presenting with typical symptoms of UTIs like painful burning sensations Increased frequency of urination Urogenital urgency. 5. Patient presenting with complaint of pain in lower back or pelvic area blood in urine cloudy and bad oduor urine 6. Patients not taking any other drugs for Uncomplicated UTIs. 7. Patients who are willing and able to understand and follow the protocol for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Patients with urinary tract stricture or any anatomical abnormality. 3. Patient with Diabetes Mellitus. 4. Patient with Hepatic & Renal insufficiency and malignancy. 5. Patient on Immunosuppressants. 6. Patient with STDs or HIV 1 and 2 7. Patient resistant to the standard control drug. nitrofurantoin 8. Patient who fails to give consent. 9. Mentally retarded person. 10. Non ambulatory and Bed ridden patients. 11. Patient willing to discontinue the drugs taking for the treatment of uncomplicated UTIs. 12. Patients with uncontrolled hypertension. 13. Patients with cardiovascular complications. 14. Patients not willing to report for follow up.

Design outcomes

Primary

MeasureTime frame
Total signs and symptoms score mentioned in synopsis And improvement in presenting complaintsTimepoint: At baseline,2nd and 3rd week—

Secondary

MeasureTime frame
ivestigations Globl scoreTimepoint: at the end of 3rd week—

Countries

India

Contacts

Public ContactDr Md Najibur Rahman

Government Tibbi College and Hospital Address

amudrshahnawaz@gmail.com9411209323

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026